| Host: | E. coli |
| Note: | STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Formulation: | Supplied as a 0.22 Mu m filtered solution in 20mM Tris, 500mM NaCl, 0.1mM EDTA, 10% Glycerol, pH 8.0. |
| Storage Instruction: | Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles. |
| Determination Method: | < 1.0 EU/Mu g of the protein by LAL method. |
| Immunoreactivity: | 1.Measured by its binding ability in a functional ELISA. Immobilized Recombinant SARS-CoV-2 Nucleocapsid at 2 Mu g/mL (100 Mu L/well) can bind Anti-Nucleocapsid antibody with a linear range of 0.12-1.64 ng/mL.|2.Measured by its binding ability in a f |
| Immunogen Region: | Met1-Ala419 |
| Immunogen: | Recombinant SARS-CoV-2 (2019-nCoV) Nucleocapsid Protein is produced by E. coli expression system. The target protein is expressed with sequence (Met1-Ala419) of SARS-COV-2 (2019-nCoV) Nucleocapsid (Accession #QHD43423.2) fused with an 6×His tag at th |
| Immunogen Sequence: | MSDNGPQNQRNAPRITFGGP SDSTGSNQNGERSGARSKQR RPQGLPNNTASWFTALTQHG KEDLKFPRGQGVPINTNSSP DDQIGYYRRATRRIRGGDGK MKDLSPRWYFYYLGTGPEAG LPYGANKDGIIWVATEGALN TPKDHIGTRNPANNAAIVLQ LPQGTTLPKGFYAEGSRGGS QASSRSSSRSRNSSRNSTPG SSRGTSPARMAGNGGDAALA LLLLDRLNQLESKMSGKGQ |
| Background | Recombinant SARS-CoV-2 (2019-nCoV) Nucleocapsid Protein is produced by E. coli expression system. The target protein is expressed with sequence (Met1-Ala419) of SARS-COV-2 (2019-nCoV) Nucleocapsid (Accession #QHD43423.2) fused with an 6×His tag at the N-terminus. |
Information sourced from Uniprot.org